Rizatriptan-Loaded Oral Fast Dissolving Films: Design and Characterizations

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Formulation Development

Background:

• Rizatriptan (RZT) is a selective 5 HT (1B/1D) serotonin receptor agonist effective for migraine treatment.
• Existing RZT nasal sprays have limitations including short half-life, potential for noncompliance, and nasopharyngeal side effects.
• Orally disintegrating dosage forms offer an alternative for improved patient compliance and reduced local adverse effects.

Purpose of the Study:

• To develop and optimize orally disintegrating films (ODFs) of rizatriptan (RZT) for enhanced anti-migraine therapy.
• To evaluate the physicochemical properties, drug release kinetics, and pharmacokinetic profile of the developed RZT ODFs.
• To compare the performance of RZT ODFs against conventional oral formulations.

Main Methods:

• Orally disintegrating films (ODFs) of RZT were prepared using maltodextrin (MTX) and pullulan (PUL) via solvent casting method (SCM).
• Formulation optimization was performed using Box-Behnken design (BBD), analyzing polymer ratios and plasticizer levels.
• Characterization included film thickness, disintegration time, mechanical properties, drug content uniformity, in vitro release, surface morphology, and solid-state analysis.

Main Results:

• Optimized RZT ODFs exhibited satisfactory stability, surface homogeneity, and amorphous drug state with no drug-polymer interactions.
• The optimized film demonstrated rapid disintegration (16 s) and favorable mechanical characteristics.
• In vitro studies showed 100% RZT release within minutes, significantly higher than conventional formulations (61% in 5 min).
• Pharmacokinetic studies in animals indicated shorter Tmax, higher Cmax, and increased AUC0-t for RZT ODFs compared to oral mini capsules.

Conclusions:

• Stable and effective orally disintegrating films of rizatriptan were successfully developed.
• The RZT ODF formulation offers rapid drug release and enhanced pharmacokinetic performance.
• This novel ODF approach presents a promising alternative for anti-migraine treatment, potentially benefiting patients with dysphagia.